{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T13:55:29Z","timestamp":1784728529763,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["09\/0591(16126)\/2022-EMR-I"],"award-info":[{"award-number":["09\/0591(16126)\/2022-EMR-I"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s13346-025-02017-1","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:37:37Z","timestamp":1764175057000},"page":"924-944","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development of sustained release injectable phospholipid-based phase transition gel matrixed with Piracetam and cannabidiol loaded nanoemulsion for amelioration of Alzheimer\u2019s therapy"],"prefix":"10.1007","volume":"16","author":[{"given":"Mohd","family":"Shahrukh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Adil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-1735","authenticated-orcid":false,"given":"Nazeer","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhan Jalees","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"2017_CR1","doi-asserted-by":"publisher","unstructured":"Attia RT, Fahmy SA, Abdel-Latif RT, Ateyya H, Fayed TW, El-Abhar HS. Cationic lipid based nanoparticles-formulated Artesunate as a neurotherapeutic agent in alzheimer\u2019s disease: targeting inflammasome activation and pyroptosis pathway. J Drug Deliv Sci Technol. 2025;107:106803. https:\/\/doi.org\/10.1016\/J.JDDST.2025.106803.","DOI":"10.1016\/J.JDDST.2025.106803"},{"key":"2017_CR2","doi-asserted-by":"publisher","unstructured":"Delbreil P, Rabanel JM, Banquy X, Brambilla D. Therapeutic nanotechnologies for alzheimer\u2019s disease: A critical analysis of recent trends and findings. Adv Drug Deliv Rev. 2022;187:114397. https:\/\/doi.org\/10.1016\/J.ADDR.2022.114397.","DOI":"10.1016\/J.ADDR.2022.114397"},{"key":"2017_CR3","doi-asserted-by":"publisher","unstructured":"Shahrukh M, Ahmad S, Zaafar M, Hasan N, Ahmad FJ. Management of alzheimer\u2019s disease with Nanotechnological interventions and novel therapeutics. Drug Dev Res. 2025;86(5):e70120. https:\/\/doi.org\/10.1002\/DDR.70120;PAGE:STRING:ARTICLE\/CHAPTER.","DOI":"10.1002\/DDR.70120;PAGE:STRING:ARTICLE\/CHAPTER"},{"key":"2017_CR4","doi-asserted-by":"publisher","unstructured":"Tiwari V, Tiwari A, Sharma A, Kumar M, Kaushik D, Sagadevan S. An optimistic approach to nanotechnology in alzheimer\u2019s disease management: an overview. J Drug Deliv Sci Technol. 2023;86:104722. https:\/\/doi.org\/10.1016\/J.JDDST.2023.104722.","DOI":"10.1016\/J.JDDST.2023.104722"},{"key":"2017_CR5","doi-asserted-by":"publisher","unstructured":"Abomosallam M et al. Neuroprotective effect of piracetam-loaded magnetic chitosan nanoparticles against thiacloprid-induced neurotoxicity in albino rats, Inflammopharmacology 2023 312. 2023:31(2):943\u2013965 https:\/\/doi.org\/10.1007\/S10787-023-01151-X","DOI":"10.1007\/S10787-023-01151-X"},{"key":"2017_CR6","doi-asserted-by":"publisher","unstructured":"Al-kuraishy HM, et al. The mechanistic role of Piracetam in the management of vascular dementia. Behav Brain Res. 2025;486:115551. https:\/\/doi.org\/10.1016\/J.BBR.2025.115551.","DOI":"10.1016\/J.BBR.2025.115551"},{"key":"2017_CR7","doi-asserted-by":"publisher","unstructured":"Tripathi A, Paliwal P, Krishnamurthy S. Piracetam Attenuates LPS-Induced Neuroinflammation and Cognitive Impairment in Rats, Cell. Mol. Neurobiol. 2017;37(8):1373\u20131386. https:\/\/doi.org\/10.1007\/S10571-017-0468-2\/FIGURES\/8","DOI":"10.1007\/S10571-017-0468-2\/FIGURES\/8"},{"key":"2017_CR8","doi-asserted-by":"publisher","unstructured":"de Paula D, Faria, et al. Cannabidiol treatment improves glucose metabolism and memory in Streptozotocin-Induced alzheimer\u2019s disease rat model: A Proof-of-Concept study. Int J Mol Sci 2022. 2022;23(3):1076. https:\/\/doi.org\/10.3390\/IJMS23031076. Page 1076.","DOI":"10.3390\/IJMS23031076"},{"key":"2017_CR9","doi-asserted-by":"publisher","unstructured":"Mahanta AK, Chaulagain B, Gothwal A, Singh J. Engineered PLGA nanoparticles for Brain-Targeted codelivery of Cannabidiol and pApoE2 through the intranasal route for the treatment of alzheimer\u2019s disease. ACS Biomater Sci Eng. 2025;11(6):3533\u201346. https:\/\/doi.org\/10.1021\/ACSBIOMATERIALS.5C00465\/ASSET\/IMAGES\/MEDIUM\/AB5C00465_0010.GIF.","DOI":"10.1021\/ACSBIOMATERIALS.5C00465\/ASSET\/IMAGES\/MEDIUM\/AB5C00465_0010.GIF"},{"key":"2017_CR10","doi-asserted-by":"publisher","unstructured":"El-Saifi N, Moyle W, Jones C, Tuffaha H. Medication Adherence in Older Patients With Dementia: A Systematic Literature Review, J. Pharm. Pract. 2018;31(3):322\u2013334. https:\/\/doi.org\/10.1177\/0897190017710524.","DOI":"10.1177\/0897190017710524"},{"key":"2017_CR11","doi-asserted-by":"publisher","unstructured":"Campbell NL, et al. Adherence and tolerability of alzheimer\u2019s disease medications: a pragmatic randomized trial. J Am Geriatr Soc. 2017;65(7):1497. https:\/\/doi.org\/10.1111\/JGS.14827.","DOI":"10.1111\/JGS.14827"},{"key":"2017_CR12","doi-asserted-by":"publisher","unstructured":"Zhang T, et al. A high-efficiency, low-toxicity, phospholipids-based phase separation gel for long-term delivery of peptides. Biomaterials. 2015;45:1\u20139. https:\/\/doi.org\/10.1016\/J.BIOMATERIALS.2014.12.042.","DOI":"10.1016\/J.BIOMATERIALS.2014.12.042"},{"key":"2017_CR13","doi-asserted-by":"publisher","unstructured":"Stankovi\u0107 T, et al. Intravenous nanoemulsions loaded with phospholipid complex of a novel Pyrazoloquinolinone ligand for enhanced brain delivery. Pharmaceutics. 2025;17(2):232. https:\/\/doi.org\/10.3390\/PHARMACEUTICS17020232\/S1.","DOI":"10.3390\/PHARMACEUTICS17020232\/S1"},{"key":"2017_CR14","doi-asserted-by":"publisher","unstructured":"Imran M, et al. Topical nanostructured lipid carrier gel of Quercetin and resveratrol: Formulation, optimization, in vitro and ex vivo study for the treatment of skin cancer. Int J Pharm. 2020;587:119705. https:\/\/doi.org\/10.1016\/J.IJPHARM.2020.119705.","DOI":"10.1016\/J.IJPHARM.2020.119705"},{"key":"2017_CR15","doi-asserted-by":"publisher","unstructured":"Jerom JP, Jalal A, Sajan AL, Soman R, Nair RH, Narayanan SP. In-vitro Neuro-2a cytotoxicity analysis and molecular Docking investigation on potential anti-amyloid agents from adiantum lunulatum. Heliyon. 2024;10(18). https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38127.","DOI":"10.1016\/j.heliyon.2024.e38127"},{"issue":"1","key":"2017_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1615\/CRITREVNEUROBIOL.V17.I1.20","volume":"17","author":"KT LePage","year":"2005","unstructured":"LePage KT, Dickey RW, Gerwick WH, Jester EL, Murray TF. On the use of Neuro-2a neuroblastoma cells versus intact neurons in primary culture for neurotoxicity studies. Crit Rev Neurobiol. 2005;17(1):27\u201350. https:\/\/doi.org\/10.1615\/CRITREVNEUROBIOL.V17.I1.20.","journal-title":"Crit Rev Neurobiol"},{"key":"2017_CR17","doi-asserted-by":"publisher","unstructured":"Kaur A, et al. Treatment of alzheimer\u2019s diseases using donepezil nanoemulsion: an intranasal approach. Drug Deliv Transl Res. 2020;10(6):1862\u201375. https:\/\/doi.org\/10.1007\/S13346-020-00754-Z\/TABLES\/5.","DOI":"10.1007\/S13346-020-00754-Z\/TABLES\/5"},{"key":"2017_CR18","doi-asserted-by":"publisher","unstructured":"Hasan N, et al. Formulation and development of novel lipid-based combinatorial advanced nanoformulation for effective treatment of non-melanoma skin cancer. Int J Pharm. 2023;632. https:\/\/doi.org\/10.1016\/J.IJPHARM.2022.122580.","DOI":"10.1016\/J.IJPHARM.2022.122580"},{"key":"2017_CR19","doi-asserted-by":"publisher","unstructured":"Kaur R, Ajitha M. Formulation of transdermal nanoemulsion gel drug delivery system of lovastatin and its in vivo characterization in glucocorticoid induced osteoporosis rat model, J. Drug Deliv. Sci. Technol. 2019;52:968\u2013978. https:\/\/doi.org\/10.1016\/j.jddst.2019.06.008","DOI":"10.1016\/j.jddst.2019.06.008"},{"key":"2017_CR20","doi-asserted-by":"publisher","unstructured":"Pragya S, Bisht, Parashar P. Nanotechnology-driven microemulsion based intranasal delivery to Neurotechnology-driven neuralink: strategies to improve management of neurodegenerative disorders. AAPS PharmSciTech. 2024;25(7). https:\/\/doi.org\/10.1208\/S12249-024-02929-0.","DOI":"10.1208\/S12249-024-02929-0"},{"key":"2017_CR21","doi-asserted-by":"publisher","unstructured":"Nehal N et al. Jan., Chitosan coated synergistically engineered nanoemulsion of Ropinirole and nigella oil in the management of Parkinson\u2019s disease: Formulation perspective and In vitro and In vivo assessment, Int. J. Biol. Macromol. 2021;167;605\u2013619. https:\/\/doi.org\/10.1016\/J.IJBIOMAC.2020.11.207","DOI":"10.1016\/J.IJBIOMAC.2020.11.207"},{"key":"2017_CR22","doi-asserted-by":"publisher","unstructured":"Azeem A, et al. Nanoemulsion components screening and selection: A technical note. AAPS PharmSciTech. 2009;10(1):69\u201376. https:\/\/doi.org\/10.1208\/S12249-008-9178-X\/METRICS.","DOI":"10.1208\/S12249-008-9178-X\/METRICS"},{"key":"2017_CR23","doi-asserted-by":"publisher","unstructured":"Esmaeili F, et al. Anti-inflammatory effects of Eugenol nanoemulsion as a topical delivery system. Pharm Dev Technol. 2016;21(7):887\u201393. https:\/\/doi.org\/10.3109\/10837450.2015.1078353.","DOI":"10.3109\/10837450.2015.1078353"},{"key":"2017_CR24","doi-asserted-by":"publisher","unstructured":"Borhade V, Pathak S, Sharma S, Patravale V. Clotrimazole nanoemulsion for malaria chemotherapy. Part I: preformulation studies, formulation design and physicochemical evaluation. Int J Pharm. 2012;431:1\u20132. https:\/\/doi.org\/10.1016\/J.IJPHARM.2011.12.040.","DOI":"10.1016\/J.IJPHARM.2011.12.040"},{"key":"2017_CR25","doi-asserted-by":"publisher","unstructured":"Mneimneh AT, Hayar B, Al Hadeethi S, Darwiche N, Mehanna MM. Application of Box-Behnken design in the optimization and development of albendazole-loaded Zein nanoparticles as a drug repurposing approach for colorectal cancer management. Int J Biol Macromol. 2024;281:136437. https:\/\/doi.org\/10.1016\/J.IJBIOMAC.2024.136437.","DOI":"10.1016\/J.IJBIOMAC.2024.136437"},{"key":"2017_CR26","doi-asserted-by":"publisher","unstructured":"Joshi R, Garud N. Development, optimization and characterization of flurbiprofen matrix transdermal drug delivery system using Box\u2013Behnken statistical design. Futur J Pharm Sci 2021. 2021;71(1):1\u201318. https:\/\/doi.org\/10.1186\/S43094-021-00199-2.","DOI":"10.1186\/S43094-021-00199-2"},{"key":"2017_CR27","doi-asserted-by":"publisher","unstructured":"Jain D, et al. Transferrin functionalized nanostructured lipid carriers for targeting Rivastigmine and Resveratrol to alzheimer\u2019s disease: Synthesis, in vitro characterization and brain uptake analysis. J Drug Deliv Sci Technol. 2023;86:104555. https:\/\/doi.org\/10.1016\/J.JDDST.2023.104555.","DOI":"10.1016\/J.JDDST.2023.104555"},{"key":"2017_CR28","doi-asserted-by":"publisher","unstructured":"Han L, et al. An injectable, low-toxicity phospholipid-based phase separation gel that induces strong and persistent immune responses in mice. Biomaterials. 2016;105:185\u201394. https:\/\/doi.org\/10.1016\/J.BIOMATERIALS.2016.08.007.","DOI":"10.1016\/J.BIOMATERIALS.2016.08.007"},{"key":"2017_CR29","doi-asserted-by":"publisher","unstructured":"Rezaeian Shiadeh SN, et al. Injectable in-Situ forming depot based on PLGA and PLGA-PEG-PLGA for Sustained-Release of risperidone: in vitro evaluation and pharmacokinetics in rabbits. Pharmaceutics. 2023;15(4):1229. https:\/\/doi.org\/10.3390\/PHARMACEUTICS15041229\/S1.","DOI":"10.3390\/PHARMACEUTICS15041229\/S1"},{"key":"2017_CR30","doi-asserted-by":"publisher","unstructured":"Kamali H, et al. Optimization and in vitro evaluation of injectable Sustained-Release of Levothyroxine using PLGA-PEG-PLGA. J Pharm Innov. 2021;16(4):688\u201398. https:\/\/doi.org\/10.1007\/S12247-020-09480-Y\/FIGURES\/10.","DOI":"10.1007\/S12247-020-09480-Y\/FIGURES\/10"},{"key":"2017_CR31","doi-asserted-by":"publisher","unstructured":"Li H, et al. An in situ-forming phospholipid-based phase transition gel prolongs the duration of local anesthesia for ropivacaine with minimal toxicity. Acta Biomater. 2017;58:136\u201345. https:\/\/doi.org\/10.1016\/J.ACTBIO.2017.06.013.","DOI":"10.1016\/J.ACTBIO.2017.06.013"},{"key":"2017_CR32","doi-asserted-by":"publisher","unstructured":"Tian W, Schulze S, Brandl M, Winter G. Vesicular phospholipid gel-based depot formulations for pharmaceutical proteins: Development and in vitro evaluation, J. Control. Release. 2010;142(3):319\u2013325. https:\/\/doi.org\/10.1016\/J.JCONREL.2009.11.006","DOI":"10.1016\/J.JCONREL.2009.11.006"},{"key":"2017_CR33","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3109\/21691401.2014.887018","volume":"43","author":"AI Journal","year":"2015","unstructured":"Journal AI, Laxmi M, Bhardwaj A, Mehta S, Mehta A. Development and characterization of nanoemulsion as carrier for the enhancement of bioavailability of Artemether development and characterization of nanoemulsion as carrier for the enhancement of bioavailability of Artemether. Nanomed Biotechnol. 2015;43:334\u201344. https:\/\/doi.org\/10.3109\/21691401.2014.887018.","journal-title":"Nanomed Biotechnol"},{"key":"2017_CR34","doi-asserted-by":"publisher","unstructured":"Nagaich U, Gulati N. Nanostructured lipid carriers (NLC) based controlled release topical gel of Clobetasol propionate: design and in vivo characterization. Drug Deliv Transl Res. 2016;6(3):289\u201398. https:\/\/doi.org\/10.1007\/S13346-016-0291-1.","DOI":"10.1007\/S13346-016-0291-1"},{"key":"2017_CR35","doi-asserted-by":"publisher","unstructured":"Khan UA et al. Jun., Parenteral Sustained Release Lipid Phase-Transition System of Ziprasidone: Fabrication and Evaluation for Schizophrenia Therapy, Drug Des. Devel. Ther. 2020;14:2237\u20132247. https:\/\/doi.org\/10.2147\/DDDT.S247196\u2019.","DOI":"10.2147\/DDDT.S247196\u2019"},{"key":"2017_CR36","doi-asserted-by":"publisher","unstructured":"Sartaj A et al. Ribociclib Nanostructured Lipid Carrier Aimed for Breast Cancer: Formulation Optimization, Attenuating In Vitro Specification, and In Vivo Scrutinization, Biomed Res. Int. 2022;2022(1):6009309. https:\/\/doi.org\/10.1155\/2022\/6009309","DOI":"10.1155\/2022\/6009309"},{"key":"2017_CR37","doi-asserted-by":"publisher","unstructured":"Ce\u00f1a V, J\u00e1tiva P. Nanoparticle crossing of blood-brain barrier: A road to new therapeutic approaches to central nervous system diseases. Nanomedicine. 2018;13(13):1513\u20136. https:\/\/doi.org\/10.2217\/NNM-2018-0139;SUBPAGE:STRING:FULL.","DOI":"10.2217\/NNM-2018-0139;SUBPAGE:STRING:FULL"},{"key":"2017_CR38","doi-asserted-by":"publisher","unstructured":"Abuzar SM, Park EJ, Seo Y, Lee J, Baik SH, Hwang SJ. Preparation and Evaluation of Intraperitoneal Long-Acting Oxaliplatin-Loaded Multi-Vesicular Liposomal Depot for Colorectal Cancer Treatment, Pharm. 2020, Vol. 12, Page 736. 2020;12(8):736. https:\/\/doi.org\/10.3390\/PHARMACEUTICS12080736","DOI":"10.3390\/PHARMACEUTICS12080736"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-02017-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-02017-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-02017-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:21:58Z","timestamp":1770304918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-02017-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2017"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-02017-1","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"20 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The author declares that they have provided their consent to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There is no conflict of interest and disclosures associated with the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The authors declare that they have no known competing financial or other interests that could have appeared to influence the work reported in this paper.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}